← Leaderboards
Rena Chiman Patel
University Of California, San Francisco
$7,764,988
Attributed
$8,324,497
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,324,497 · 7
By mechanism
R01$5,480,406 · 2
R21$1,296,461 · 3
K23$849,619 · 1
R34$698,011 · 1
Top collaborators
- Lisa Lynn Abuogi2 shared
- Anjuli Dawn Wagner2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- John Daniel Kelly$1,673,513
- Stephen Schueller$3,291,012
- Philip Darney$987,748
- Craig Franklin$17,692,971
- Urvi M. Parikh$1,674,974
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesAntiretroviral TherapyAfrica South Of The SaharaRegimenKenyaCohortCaringViralGuidelinesPreventionAnti-Retroviral AgentsPublic HealthInterviewAdherenceMaternal MorbidityProviderPregnancyHealth SystemBaseSamplingDrug InteractionsDrug KineticsHormonal ContraceptionPlasma
Grant awards (25)
A tale of two cities: Understanding geographic differences by region and rurality in HIV care outcomes in the U.S.$571,567
R01 · FY2025 · MH · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$329,173
R01 · FY2025 · AI · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$1
R01 · FY2025 · AI · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$611,153
R01 · FY2024 · AI · contact PI
The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.$548,386
R01 · FY2024 · MH · contact PI
The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.$645,647
R01 · FY2023 · MH · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$631,398
R01 · FY2023 · AI · contact PI
The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.$11,325
R01 · FY2023 · MH · contact PI
The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.$722,272
R01 · FY2022 · MH · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$693,687
R01 · FY2022 · AI · contact PI
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives$715,797
R01 · FY2021 · AI · contact PI
Using systems science to optimize the impact of point-of-care viral load testing for pediatric HIV management$191,066
R21 · FY2021 · MH · contact PI
Optimizing viral suppression for pregnant and postpartum women living with HIV through HIV resistance testing (Opt4Mamasplus)$292,077
R21 · FY2020 · AI · contact PI
Using systems science to optimize the impact of point-of-care viral load testing for pediatric HIV management$229,941
R21 · FY2020 · MH · contact PI
Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)$342,062
R34 · FY2019 · MH · contact PI
A pharmacokinetic evaluation of new first-line antiretroviral therapy regimens and contraceptive implants among HIV-positive women in Kenya$230,709
R21 · FY2019 · AI · contact PI
Optimizing viral suppression for pregnant and postpartum women living with HIV through HIV resistance testing (Opt4Mamasplus)$161,350
R21 · FY2019 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$147,927
K23 · FY2019 · AI · contact PI
Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)$355,949
R34 · FY2018 · MH · contact PI
A pharmacokinetic evaluation of new first-line antiretroviral therapy regimens and contraceptive implants among HIV-positive women in Kenya$191,318
R21 · FY2018 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$147,927
K23 · FY2018 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$194,891
K23 · FY2017 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$174,820
K23 · FY2016 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$146,254
K23 · FY2015 · AI · contact PI
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants$37,800
K23 · FY2015 · AI · contact PI